Is BIVI or BMY more undervalued in 2026?

CirclFi compares BioVie Inc. (BIVI) and Bristol-Myers Squibb Company (BMY) using 13 institutional-grade valuation models. BIVI has a Quality of Company score of 3.2/10 while BMY scores 9.9/10.

Which is a better buy — BIVI or BMY?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do BIVI and BMY valuations compare?

BIVI at $1.42 and BMY at $57.18 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

BIVI vs BMY Valuation Comparison 2026 — Intrinsic Value Analysis

BIVI

Pharmaceutical Preparations

BioVie Inc.

Quality

3.2

out of 10

Value Trap

LOW

Price

$1.42

Last close

Models

7/13

Active

BMY

Pharmaceutical Preparations

Bristol-Myers Squibb Company

Quality

9.9

out of 10

Value Trap

SAFE

Price

$57.18

Last close

Models

12/13

Active

Model-by-Model Comparison

Model	Type	BIVI Fair Value	BIVI Upside	BMY Fair Value	BMY Upside
Bayesian DCF	Intrinsic	$1.44	+1.6%	$122.58	+114.4%
Earnings Power Value	Intrinsic	—	—	$52.56	-8.1%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$0.27	-84.1%	$59.62	+4.3%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for BIVI vs BMY — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

BIVI vs BMY — Which Stock Is More Undervalued?

BMY scores higher with a 9.9/10 quality rating vs BIVI's 3.2/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing BioVie Inc. (BIVI) and Bristol-Myers Squibb Company (BMY) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

BIVI currently trades at $1.42 with a QOC of 3.2/10, while BMY trades at $57.18 with a QOC of 9.9/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).